3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
9
Recurrence
4
Ovarian Neoplasms
4
Glioblastoma
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Radiation Pneumonitis
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Patients With Any Advanced Solid Tumors
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Mesothelioma, Malignant
1
Melanoma, Cutaneous Malignant
1
Lymphangioleiomyomatosis
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophagogastric Adenocarcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
Sirolimus
9
Everolimus
3
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Respiratory Function Tests
1
Phlebotomy
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Genetic Testing
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphangioleiomyomatosis
×
nintedanib
×
Clear all
NCT03062943
2022-09-28
LAM
IRCCS Multimedica
Phase 2
Completed
30 enrolled